Preliminary study of PPARA regulate the ferroptosis of hepatocellular carcinoma to prevent disease deterioration.
10.3760/cma.j.cn112150-20221124-01148
- Author:
Jia Jia CAI
1
;
Min Ting LIANG
2
;
Wan Qing LI
3
;
Wei Yun ZHANG
1
;
Xiao LI
1
;
Zhao Hui SUN
4
Author Information
1. Department of Laboratory Medicine, General Hospital of Southern Theatre Command of PLA, Guangzhou 510010, China.
2. Department of Laboratory Medicine, General Hospital of Southern Theatre Command of PLA, Guangzhou 510010, China Department of Biochemistry and Molecular Biology, Sun Yat-sen University Zhongshan School of Medicine, Guangzhou 510010, China.
3. Department of Laboratory Medicine, General Hospital of Southern Theatre Command of PLA, Guangzhou 510010, China Graduate School, Guangzhou University of Chinese Medicine, Guangzhou 510010, China.
4. Department of Laboratory Medicine, General Hospital of Southern Theatre Command of PLA, Guangzhou 510010, China Department of Biochemistry and Molecular Biology, Sun Yat-sen University Zhongshan School of Medicine, Guangzhou 510010, China Graduate School, Guangzhou University of Chinese Medicine, Guangzhou 510010, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Carcinoma, Hepatocellular/pathology*;
Ferroptosis;
Liver Neoplasms/pathology*;
Peroxisome Proliferator-Activated Receptors/genetics*
- From:
Chinese Journal of Preventive Medicine
2023;57(7):1068-1074
- CountryChina
- Language:Chinese
-
Abstract:
To explore whether PPARA is involved in the process of ferroptosis in hepatoma cells, peroxisome proliferator activated receptor (PPARA) was comprehensively analyzed in hepatocellular carcinoma (HCC) through public database and experimental data, including the expression, the functions and the potential roles of tumor progression. The research design is experimental research,data analysis based on bioinformatics and cell experiment. From January 2022 to August 2022, relevant cell experiments were conducted in the Basic Medical Laboratory of the General Hospital of the Southern Theatre of the Chinese People's Liberation Army. The expression and the correlation with clinicopathologic features of PPARA in HCC were analyzed by The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. To study the protein expression of PPARA in HCC and normal tissues through the Human Protein Atlas (HPA). The protein-protein interaction (PPI) network between PPARA and the core factor of ferroptosis was constructed based on Search Tool for the Retrival of Interacting Genes/Protein (STRING) database, then, the correlation between PPARA and the core gene Glutamate-cysteine Ligase Catalytic Subunit (GCLC) was analyzed by Gene Expression Profiling Interactive Analysis (GEPIA). Assessed the expression of PPARA in HCC cell lines SK-HEP-1, SMMC-7721, MHCC-97H, BEL-7402 and normal liver cell L02 by Western Blot (WB) and the changes of PPARA expression after 48h treatment with ferroptosis inducer Erastin were observed. Single factor analysis of variance was used to compare the expression of PPARA between groups in GEPIA database. The expression of PPARA in GSE25097 and GSE112790 data was compared by rank sum test. Survival analysis was performed using time series test method. The difference of PPARA expression between clinical and pathological features was compared using the Kruskal-Wallis test. The correlation between the expression of GCLC and PPARA was compared by the method of Spearman correlation. The expression of PPARA in cell lines was compared by paired T test. The results showed that the RNA and protein expression of PPARA in HCC was lower than that in normal tissues (P<0.05). PPARA alterations were correlated with patient clinicopathological features and prognosis (P<0.05). The PPI constructed by STRING database suggests that PPARA interact with the key factors of ferroptosis, such as NFE2 like bZIP transcription factor 2 (NFE2L2), Heme Oxygenase 1 (HMOX1), Tumor Protein P53 (TP53), GCLC, Dipeptidyl Peptidase 4 (DPP4), Citrate Synthase (CS), Arachidonate 15-Lipoxygenase (ALOX15) and Acyl-CoA Synthetase Long Chain Family Member 4 (ACSL4). Furthermore, the PPARA was significantly associated with GCLC validated via GEPIA database(R=0.6, P<0.05). The expression of PPARA increased after treatment with ferroptosis inducer Erastin for 48 h by WB. In conclusion, the expression of PPARA is lower in HCC with a poor prognosis. PPARA interacts with GCLC in regulating ferroptosis in HCC.
